STOCK TITAN

Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

Presentation Date: December 7, 2022
Time: 9:00am EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2937/47190

Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. To attend the conference and request a meeting, register here:

https://planetmicrocapshowcase.com/signup

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham (Media)
CORE IR
917-885-7378
julesa@coreir.com

Bret Shapiro (Investors)
Senior Managing Partner
CORE IR
(561) 479.8566
brets@coreir.com


NEMAURA MEDICAL INC

OTC:NMRD

NMRD Rankings

NMRD Latest News

NMRD Stock Data

2.46M
14.84M
48.62%
4.41%
0.18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
New York

About NMRD

nemaura medical inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. the company provides sugarbeat, a non-invasive continuous glucose monitoring device for use by persons with type i and type ii diabetes, as well as for screening pre-diabetic patients. it has a license agreement with healthimation, llc, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for type 2 diabetes, prediabetes, and general wellness; the why wait app; and common law trademarks which incorporate the mark why wait or whywait and the use of licensed marks. nemaura medical inc. was founded in 2009 and is based in new york, new york.